Key Account Manager I (Belo Horizonte)

Brazil

Apply with AI Apply

Not SpecifiedCompensation

Entry Level & New Grad, Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceutical, PharmaceuticalsIndustries

Requirements

Candidates must be based in Belo Horizonte and possess a Bachelor's degree in a related business or scientific discipline. Required experience includes pharmaceutical/biotechnology sales or key account management, particularly with high-cost products. Experience with rare diseases and hands-on interaction with third parties, patient organizations, and specialty pharmacy distribution for high-cost products requiring patient access services coordination is also required.

Responsibilities

The Key Account Manager will represent PTC's products to medical professionals within an assigned geographic region, building and maintaining relationships with Healthcare Providers (HCPs) and clients. Responsibilities include generating sales, communicating clinical and economic benefits, educating healthcare staff, identifying growth opportunities, and executing regional action plans to meet sales goals. The role involves understanding and implementing marketing plans, driving patient identification initiatives, managing relationships with health authorities, KOLs, patient organizations, and payors, resolving access and reimbursement issues, and providing product training. The incumbent will also communicate drug information, maintain clinical knowledge, and collaborate with internal teams to share best practices and drive business.

Skills

Pharmaceutical Sales

Relationship Building

Client Education

Sales Strategy

Market Analysis

Communication

Cross-functional Collaboration

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees